focus -WSS

focus

author：focus 2025-09-27 12:56:30 - browse：3

empty test tubes in the hand. -- first opinion coverage from STAT — Adobe

The Food and Drug Administration on Friday announced its intention to start regulating tests developed in laboratories — closing the “Theranos loophole” that has allowed inaccurate tests to slip through the cracks.

Lawmakers came close last year to passing a bill that would have given the FDA this authority, but it was ultimately rejected by Republicans who sympathized with the labs in academic medical centers and hospitals that opposed the provision. FDA Commissioner Robert Califf said at the time that if the bill failed, the agency would take matters into its own hands.

The proposed rule fulfills that promise, adding lab diagnostics to the list of devices that fall under FDA enforcement — a move that patient groups and non-lab test makers support, and that laboratories are likely to dispute. When the FDA started regulating medical devices in 1976, lab-developed tests were simple and offered mostly to local patient populations. The agency generally allowed labs to use these tests without submitting proof of their efficacy.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： STAT Health News: Apple Watch import ban, Pfizer fumbles, etc

hotspot

focus

WSS

A deep dive into Applied Therapeutics’ data, and questions on Cassava

Precocious puberty in girls comes with mental health risks

Change Healthcare cyberattack prompts Medicare loan program

Medicare drug price negotiation hasn't dried up venture capital

CDC marks new Covid

What STAT readers think about the FDA and patient advocacy

hotspot

focus

entertainment

Jerome Adams on the need for new antivirals for Covid

Former medical device CEO who sold dummy, plastic parts convicted of fraud

Hepatitis C has a cure — but many Americans still lack access to it

Readout LOUD podcast: Venture capital turmoil, obesity drug competition

After affirmative action ruling, medical educators look to 'holistic review'

Drinking less cuts risk of oral cavity, esophageal cancer: Report

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Three trends to watch in biotech in 2024

BioMarin wins approval for gene therapy to treat hemophilia A

A deep dive into Applied Therapeutics’ data, and questions on Cassava

knowledge

Editas, Vertex strike deal on CRISPR

Former medical device CEO who sold dummy, plastic parts convicted of fraud

Readout Newsletter: The latest on Moderna, Apellis, and Merck

Albert Bourla of Pfizer: worst biopharma CEO of 2023

In surprise move, FDA calls for advisory committee on Lilly's Alzheimer's drug

Readout Newsletter: Amylyx, Alto Neuro, and Eli Lilly for the Oscars

leisure time

hotspot

focus

Wikipedia